Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy. A FILO Study.

NCT05621148 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT05621148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05621148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy. A FILO Study.
Lead sponsor
French Innovative Leukemia Organisation
Phase
Observational
Overall status
Completed
Start date
January 25, 2023
Completion date
March 31, 2024
Enrollment
152 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bruton tyrosine kinase inhibitor, cll, refractory, cll, relapsed, small lymphocytic leukemia